Clinical Trials Logo

Clinical Trial Summary

Our goal in this study is to investigate the extent of endogenous nitrosation of nornicotine in smokeless tobacco users as a function of nornicotine content in smokeless products. This study will lead to an understanding of the endogenous formation of NNN from nornicotine in humans, and will also investigate the effect of the reduction of nornicotine content in smokeless tobacco on the extent of endogenous NNN formation. The knowledge gained in this study will lead to the development of recommendations for the regulation, or potentially elimination, of nornicotine in smokeless tobacco products in order to minimize exposure to NNN in the users of these products.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03998735
Study type Interventional
Source Masonic Cancer Center, University of Minnesota
Contact Hanna Vanderloo, RN, MSN
Phone 612-624-4983
Email hannav@umn.edu
Status Recruiting
Phase Phase 1
Start date October 19, 2021
Completion date October 2026

See also
  Status Clinical Trial Phase
Completed NCT00265681 - Telephone Counseling for Snuff Users N/A
Completed NCT01249339 - In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus Phase 1
Completed NCT01369693 - In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus Phase 1
Withdrawn NCT01100216 - Human Laboratory Study of Smokeless Tobacco Products N/A
Active, not recruiting NCT02994082 - Treating Smokeless Tobacco Use in Rural Veterans N/A
Completed NCT00414180 - Bupropion SR for Treating Smokeless Tobacco Use Phase 3